Bank of New York Mellon Corp Purchases 1,253,385 Shares of Certara, Inc. (NASDAQ:CERT)

Bank of New York Mellon Corp raised its holdings in shares of Certara, Inc. (NASDAQ:CERT) by 169.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,995,071 shares of the company’s stock after purchasing an additional 1,253,385 shares during the period. Bank of New York Mellon Corp owned 1.24% of Certara worth $21,248,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Brown Brothers Harriman & Co. bought a new stake in Certara in the 3rd quarter worth approximately $27,292,000. Kopion Asset Management LLC grew its holdings in Certara by 46.0% during the 4th quarter. Kopion Asset Management LLC now owns 555,643 shares of the company’s stock valued at $5,918,000 after purchasing an additional 175,005 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in Certara by 40.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock worth $45,691,000 after acquiring an additional 1,128,006 shares in the last quarter. Vontobel Holding Ltd. bought a new position in shares of Certara during the fourth quarter valued at approximately $1,295,000. Finally, Principal Financial Group Inc. lifted its position in Certara by 3.1% during the fourth quarter. Principal Financial Group Inc. now owns 531,445 shares of the company’s stock valued at $5,660,000 after acquiring an additional 15,739 shares during the last quarter. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Barclays raised their price target on shares of Certara from $12.00 to $13.00 and gave the stock an “equal weight” rating in a report on Friday, February 28th. Stephens reaffirmed an “overweight” rating and set a $17.00 target price on shares of Certara in a research note on Thursday, February 27th. William Blair restated a “market perform” rating on shares of Certara in a report on Thursday, February 27th. Finally, TD Cowen assumed coverage on shares of Certara in a research report on Thursday, February 27th. They set a “buy” rating and a $16.00 price objective for the company. Four analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $15.83.

Certara Stock Down 3.9 %

Shares of Certara stock opened at $11.27 on Tuesday. The company has a market cap of $1.81 billion, a P/E ratio of -56.35, a PEG ratio of 9.29 and a beta of 1.60. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. Certara, Inc. has a one year low of $9.41 and a one year high of $19.39. The firm has a fifty day moving average of $12.57 and a two-hundred day moving average of $11.59.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.